Osteoporosis Drugs Market in BRIC Nations, Growth, Analysis and Forecasts to 2019
ReportsWeb.com published “Osteoporosis Drugs Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
(EMAILWIRE.COM, October 13, 2017 ) About osteoporosis
Osteoporosis, or porous bone, is a disease characterised by low bone density and structural deterioration of bone tissue, leading to fragile bones. This increases the risk of fractures. Osteoporosis mainly affects women, but can also affect men. In women, bone loss occurs very rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement occurs too slowly. Risk factors for osteoporosis that cannot be controlled include gender, age, body size (low body weight), ethnicity, and family history. Risk factors that can be controlled include sex hormones, medication use, calcium and vitamin intake, alcohol intake, and smoking.
Publisher's analysts forecast the osteoporosis drugs market in BRIC nations to grow at a CAGR of 17.43% over the period 2014-2019.
For more information http://www.reportsweb.com/osteoporosis-drugs-market-in-bric-nations-2015-2019
Covered in this report
This report covers the present scenario and the growth prospects of the osteoporosis drugs market in BRIC nations for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various pharmaceutical products used in the treatment of osteoporosis. Pharmaceutical products are classified as branded and generic drugs.
Publisher's report, Osteoporosis Drugs Market in BRIC Nations 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Brazil, Russia, India, and China; it also covers the landscape of the osteoporosis drugs market in BRIC nations and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.
Key countries
- Brazil
- China
- India
- Russia
Key vendors
- Amgen
- Eli Lilly
- Merck
- Novartis
Request Sample Copy http://www.reportsweb.com/inquiry&RW0001232287/sample
Other prominent vendors
- Abiogen Pharma
- Deltanoid Pharmaceuticals
- F. Hoffmann La Roche
- GlaxoSmithKline
- IMMD
- Ligand Pharmaceuticals
- Pantarhei Bioscience
- Pfizer
- PhytoHealth
- Radius Health
- UPSHER-SMITH LABORATORIES
- Zosano Pharma
Market driver
- Increase in aging population
- For a full, detailed list, view our report
Market challenge
- Multiple patent expiries
- For a full, detailed list, view our report
Market trend
- Shift toward anabolic treatments
- For a full, detailed list, view our report
Make an enquiry: http://www.reportsweb.com/inquiry&RW0001232287/buying
Osteoporosis, or porous bone, is a disease characterised by low bone density and structural deterioration of bone tissue, leading to fragile bones. This increases the risk of fractures. Osteoporosis mainly affects women, but can also affect men. In women, bone loss occurs very rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement occurs too slowly. Risk factors for osteoporosis that cannot be controlled include gender, age, body size (low body weight), ethnicity, and family history. Risk factors that can be controlled include sex hormones, medication use, calcium and vitamin intake, alcohol intake, and smoking.
Publisher's analysts forecast the osteoporosis drugs market in BRIC nations to grow at a CAGR of 17.43% over the period 2014-2019.
For more information http://www.reportsweb.com/osteoporosis-drugs-market-in-bric-nations-2015-2019
Covered in this report
This report covers the present scenario and the growth prospects of the osteoporosis drugs market in BRIC nations for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various pharmaceutical products used in the treatment of osteoporosis. Pharmaceutical products are classified as branded and generic drugs.
Publisher's report, Osteoporosis Drugs Market in BRIC Nations 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Brazil, Russia, India, and China; it also covers the landscape of the osteoporosis drugs market in BRIC nations and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.
Key countries
- Brazil
- China
- India
- Russia
Key vendors
- Amgen
- Eli Lilly
- Merck
- Novartis
Request Sample Copy http://www.reportsweb.com/inquiry&RW0001232287/sample
Other prominent vendors
- Abiogen Pharma
- Deltanoid Pharmaceuticals
- F. Hoffmann La Roche
- GlaxoSmithKline
- IMMD
- Ligand Pharmaceuticals
- Pantarhei Bioscience
- Pfizer
- PhytoHealth
- Radius Health
- UPSHER-SMITH LABORATORIES
- Zosano Pharma
Market driver
- Increase in aging population
- For a full, detailed list, view our report
Market challenge
- Multiple patent expiries
- For a full, detailed list, view our report
Market trend
- Shift toward anabolic treatments
- For a full, detailed list, view our report
Make an enquiry: http://www.reportsweb.com/inquiry&RW0001232287/buying
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results